Teachers Retirement System of The State of Kentucky Makes New Investment in BridgeBio Pharma, Inc. $BBIO

Teachers Retirement System of The State of Kentucky purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,868 shares of the company’s stock, valued at approximately $564,000.

Several other large investors have also modified their holdings of BBIO. Victory Capital Management Inc. increased its stake in shares of BridgeBio Pharma by 42.0% during the 3rd quarter. Victory Capital Management Inc. now owns 479,680 shares of the company’s stock worth $24,915,000 after purchasing an additional 141,800 shares in the last quarter. Royce & Associates LP lifted its stake in BridgeBio Pharma by 4.8% in the 3rd quarter. Royce & Associates LP now owns 232,923 shares of the company’s stock valued at $12,098,000 after buying an additional 10,618 shares in the last quarter. Okabena Investment Services Inc. acquired a new stake in BridgeBio Pharma during the 3rd quarter valued at $816,000. Huntington National Bank grew its holdings in BridgeBio Pharma by 111.7% during the 3rd quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after buying an additional 392 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd purchased a new position in BridgeBio Pharma during the third quarter worth $31,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BBIO has been the subject of a number of analyst reports. Leerink Partners boosted their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. HC Wainwright increased their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Wells Fargo & Company lifted their price objective on BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Morgan Stanley boosted their target price on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, Sanford C. Bernstein assumed coverage on shares of BridgeBio Pharma in a research note on Thursday, December 11th. They set an “outperform” rating and a $94.00 price target on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.50.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Positive Phase 3 BBP-418 data in LGMD2I/R9 strengthens the clinical and revenue upside narrative for BridgeBio’s rare-disease pipeline; that result is being argued as expanding the company’s long-term bull case. Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)?
• Positive Sentiment: Truist raised its price target to $95 and kept a Buy rating, citing recent commercial traction (pre-announced Attruby sales) — a notable analyst endorsement that can support investor confidence and boost valuation expectations. Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
• Positive Sentiment: Consensus analyst sentiment remains constructive (MarketBeat/AmericanBankingNews report a “Moderate Buy” consensus and an $82.50 average target), suggesting broad Wall Street support despite recent volatility. BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Reported short-interest data in the feed is inconsistent/unclear (entries show 0 shares and NaN changes), so there’s no clear signal from short-sellers to explain today’s move.
• Negative Sentiment: Director Andrea Ellis sold 64,921 shares (~$4.21M) on March 4, cutting her stake by ~77.7% — insider selling can be interpreted negatively by the market even when for personal/liquidity reasons. BridgeBio Pharma (NASDAQ:BBIO) Director Sells $4,211,425.27 in Stock
• Negative Sentiment: Recent quarterly results showed an EPS miss (reported ($1.00) vs. consensus ($0.75)), reminding investors that BridgeBio is still delivering mixed near-term financials despite big revenue improvements year-over-year.

Insider Buying and Selling

In related news, CAO Maricel Apuli sold 510 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $74.31, for a total value of $37,898.10. Following the sale, the chief accounting officer directly owned 123,945 shares of the company’s stock, valued at approximately $9,210,352.95. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 28,053 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67. Following the completion of the sale, the chief executive officer owned 234,451 shares of the company’s stock, valued at approximately $16,737,456.89. The trade was a 10.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 229,095 shares of company stock worth $16,247,760 over the last ninety days. Insiders own 18.20% of the company’s stock.

BridgeBio Pharma Stock Down 1.2%

BBIO stock opened at $65.36 on Friday. The stock has a market capitalization of $12.67 billion, a price-to-earnings ratio of -17.29 and a beta of 1.13. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $84.94. The stock’s fifty day simple moving average is $73.64 and its 200-day simple moving average is $65.34.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million during the quarter, compared to analysts’ expectations of $150.71 million. During the same period in the prior year, the firm earned ($1.40) EPS. The company’s revenue was up 2521.2% on a year-over-year basis. As a group, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.